Best of ASCO - 2014 Annual Meeting

 

Welcome

Attend this session at the
2019 ASCO Annual Meeting!


Session: Developmental Immunotherapy and Tumor Immunobiology

Type: Poster Session

Time: Saturday June 1, 8:00 AM to 11:00 AM

Location: Hall A

Application of artificial intelligence to predict a new class of novel synthetic lethal targets.

Sub-category:
New Targets and New Technologies (IO)

Category:
Developmental Immunotherapy and Tumor Immunobiology

Meeting:
2019 ASCO Annual Meeting

Abstract No:
2598

Poster Board Number:
Poster Session (Board #242)

Citation:
J Clin Oncol 37, 2019 (suppl; abstr 2598)

Author(s): Spyro Mousses, David Schneider, Jeff Kiefer, Pieter Derdeyn, Kendyl Douglas, Abhishek Kothari, Daniel D. Von Hoff, Chris Yoo; Systems Oncology, Scottsdale, AZ; Systems Imagination, Inc., Tempe, AZ; Translational Genomics Research Institute, Phoenix, AZ

Abstract Disclosures

Abstract:

Background: Synthetic lethal targets are proteins that are contextually vulnerable. Inhibitors of PARP1, for example, selectively produce a lethal phenotype in the context of cancer cells which have lost BRCA1 or BRCA2 function. As a high mutation rate is a hallmark of many cancers, targeting synthetic lethal interactions to selectively inhibit cancer cells with altered genetic backgrounds may increase the specificity and efficacy of therapeutics. Recently, clinical trials have targeted synthetic lethal pairs such as EGFR and BRAF, TP53 and BCL2, and PTEN and CHD1. Previous attempts to identify synthetic lethal targets have relied on empirical results from published studies of biological pathways perturbed in cancer cells. Developing strategies to rapidly identify synthetic lethals by combining multiple experimental and computational approaches would result in a new class of potential cancer drug targets beyond the existing efforts that rely on single experimental or computational methods alone. Methods: Here we present Expansive AI, an artificial intelligence augmented knowledge network that enables rapid hypothesis generation for accelerated discovery research. Using a purpose-built, hypergraph database of massive, integrated genomic and biomedical data, we can query all synthetic lethals and their component genes, as well as a wealth of data related to these genes. The database of biological data includes 11,000+ cancer genomes from TCGA, prior knowledge resources such as gene ontology and pathway resources, and experimental data including chemical and protein interaction and patent data. The hypergraph’s architecture allows for linking and nesting data, enabling efficient extraction of biologically-relevant features. Results: Using these features, a neural network classified 540 new candidate pairs that have previously not been reported. The candidate pairs were filtered to include only known oncogenes and least-studied genes. This produced a list of gene pairs which may represent the most novel class of synthetic lethal target candidates identified to date. Conclusions: We highlight the results of this AI-based approach and discuss validation efforts of the predicted interactions in specific cancer contexts.

 
Other Abstracts in this Sub-Category:

 

1. A phase II, randomized, double-blind, placebo-controlled trial evaluating efficacy and safety of namodenoson (CF102), an A3 adenosine receptor agonist (A3AR), as a second-line treatment in patients with Child-Pugh B (CPB) advanced hepatocellular carcinoma (HCC).

Meeting: 2019 ASCO Annual Meeting Abstract No: 2503 First Author: Salomon M. Stemmer
Category: Developmental Immunotherapy and Tumor Immunobiology - New Targets and New Technologies (IO)

 

2. Results from a first-in-man, open label, safety and tolerability trial of CAN04 (nidanilimab), a fully humanized monoclonal antibody against the novel antitumor target, IL1RAP, in patients with solid tumor malignancies.

Meeting: 2019 ASCO Annual Meeting Abstract No: 2504 First Author: Ahmad Awada
Category: Developmental Immunotherapy and Tumor Immunobiology - New Targets and New Technologies (IO)

 

3. Determination of the recommended phase II dose of birinapant in combination with pembrolizumab: Results from the dose-escalation phase of BPT-201.

Meeting: 2019 ASCO Annual Meeting Abstract No: 2506 First Author: Russell J. Schilder
Category: Developmental Immunotherapy and Tumor Immunobiology - New Targets and New Technologies (IO)

 

More...